medicaid glp-1 States Are Walking Back Coverage for GLP-1s Weight-loss drug coverage extends to

Starting at lower doses and increasing more slowly often produces better long-term compliance with fewer side effects

These medications include GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy, Rybelsus) and liraglutide, as well as dual GIP/GLP-1 receptor agonists like tirzepatide (Mounjaro, Zepbound)

For children and adolescents aged 2 to 18, providers assess BMI using a percentile scale based on gender and age, defining obesity as a BMI at or above the 95th percentile and overweight as falling between the 85th and 94th percentiles (3)

Telogen effluvium is a common type of sudden hair loss that typically results from stress or shock

Retatrutide: GLP-1 + GIP + Glucagon (Triple Agonist) Retatrutide (LY3437943) keeps the same two receptors as tirzepatide, then adds a third: glucagon

metabolized by proteolytic cleavage and subsequent beta-oxidation (Kommu & Whitfield, 2024)